A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas and - due to innovations in manufacturing - could make future cellular immunotherapies less expensive and more accessible to ...

French biotech Innate Pharma is recruiting natural-born killers to target B cell non-Hodgkin lymphoma (B-NHL). The company’s tetraspecific antibody controlled tumors and improved survival in mice and ...

Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive malignancy most frequently involving the nasal cavity and upper aerodigestive tract, although it may present in other extranodal ...

Single-agent CD19 CAR-NK cell therapy achieved a complete response in third-line Waldenstrom macroglobulinemia (WM), a type of non-Hodgkin lymphoma Second patient maintains an ongoing complete ...

The researchers argue that their findings, published in Scientific Reports, could help clinicians anticipate which patients ...

Top experts have developed new 'natural killer' cells to fight off cancer and lower the risk of disastrous immune effects. Researchers at Harvard Medical School and the Massachusetts Institute of ...

Can the immune system cure cancer? Dr. Patrick Soon-Shiong discusses a paradigm shift using NK cells to treat tumors without ...

Corvus Pharmaceuticals (CRVS) announced the presentation of final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma ...

Vigencell Inc. plans to seek conditional approval in South Korea for VT-EBV-N, an antigen-specific killer T-cell therapy for natural killer T-cell lymphoma, after gaining positive top-line data from a ...

Patients in 200 mg BID cohort had median progression free survival of 6.2 months and median overall survival of 28.1 months, comparing favorably to results with other therapies Data supports ongoing ...